NCT02094794 - Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

May 12, 2014

Primary Completion Date

May 26, 2026

Study Completion Date

May 26, 2026

Conditions

Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid Leukemia

Interventions

DRUG

etoposide

Given IV

DRUG

cyclophosphamide

Given IV

RADIATION

total marrow irradiation

Undergo TMLI

PROCEDURE

allogeneic hematopoietic stem cell transplantation

Undergo allogeneic peripheral blood stem cell or bone marrow transplant

PROCEDURE

allogeneic bone marrow transplantation

Undergo allogeneic peripheral blood stem cell or bone marrow transplant

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER